Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Grand Pharmaceutical Group Limited ( (HK:0512) ) has shared an update.
Grand Pharmaceutical Group Limited has announced that China’s National Medical Products Administration has accepted the new drug application for TLX591-CDx (Illuccix), its innovative radionuclide-drug conjugate for diagnosing prostate cancer, marking a key milestone in the company’s nuclear medicine portfolio. The filing is supported by Phase III data in Chinese patients showing a high positive predictive value of 94.8% and significant impact on treatment decisions, with over two-thirds of patients having their treatment plans altered after TLX591-CDx imaging. Alongside the planned Phase III trial in China for the therapeutic RDC TLX591, the accepted NDA strengthens Grand Pharmaceutical’s theranostic strategy in prostate cancer and positions the group to leverage the strong global track record and growing sales of TLX591-CDx as it seeks to bring advanced, integrated diagnostic and treatment solutions to China’s oncology market.
The most recent analyst rating on (HK:0512) stock is a Buy with a HK$8.50 price target. To see the full list of analyst forecasts on Grand Pharmaceutical Group Limited stock, see the HK:0512 Stock Forecast page.
More about Grand Pharmaceutical Group Limited
Grand Pharmaceutical Group Limited is a Bermuda-incorporated pharmaceutical company with a comprehensive presence in nuclear medicine anti-tumor diagnosis and treatment, spanning R&D, production, distribution and sales. Through global R&D centers in Boston and Chengdu, manufacturing facilities in Boston, Frankfurt, Singapore and Chengdu, and a sales network covering more than 50 countries and regions, the group focuses on innovative radionuclide-drug conjugates (RDCs) for cancers such as liver, prostate and brain cancer, and holds exclusive Greater China rights to several RDC products developed by Telix Pharmaceuticals.
Average Trading Volume: 5,735,278
Technical Sentiment Signal: Buy
Current Market Cap: HK$27.72B
See more data about 0512 stock on TipRanks’ Stock Analysis page.